<p>Eyepoint Pharmaceuticals, Inc.（纳斯达克代码：EYPT - 获取免费报告）周一股价上涨了 8.6%。该公司股价最高达到 12.46 美元，最后交易价格为 12.58 美元。在午盘交易中，交易量为 292,616 股，较平均交易量 911,497 股下降了 68%。该股票之前的收盘价为 11.58 美元。</p>
<h2>华尔街分析师观点</h2>
<ul>
<li>你可能不知道的突破性动量股</li>
</ul>
<p>几家研究公司最近对 EYPT 进行了评估。HC Wainwright 将 Eyepoint Pharmaceuticals 的目标价格从 22.00 美元上调至 23.00 美元，并在 8 月 6 日的研究报告中给予该公司 “买入” 评级。Chardan Capital 在 8 月 7 日的研究报告中重申了 “买入” 评级，并对 Eyepoint Pharmaceuticals 的股票设定了 27.00 美元的目标价格。Mizuho 在 10 月 20 日的研究报告中对 Eyepoint Pharmaceuticals 的股票设定了 28.00 美元的目标价格。加拿大皇家银行在 11 月 6 日的研究报告中将 Eyepoint Pharmaceuticals 的目标价格从 28.00 美元上调至 39.00 美元，并给予该公司 “跑赢大盘” 评级。最后，Weiss Ratings 在 10 月 8 日的研究报告中重申了 Eyepoint Pharmaceuticals 的 “卖出（d-）” 评级。五位股票研究分析师对该股票给予了 “买入” 评级，一位分析师给予了 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，平均目标价格为 30.00 美元。</p>
<p><strong>获取我们关于 Eyepoint Pharmaceuticals 的最新股票报告</strong></p>
<h2>Eyepoint Pharmaceuticals 股价上涨 12.3%</h2>
<p>该股票的市值为 10.8 亿美元，市盈率为-4.84，贝塔值为 1.85。该公司的 50 日移动平均线为 12.76 美元，200 日移动平均线为 10.49 美元。</p>
<p>Eyepoint Pharmaceuticals（纳斯达克代码：EYPT - 获取免费报告）最近于 11 月 5 日发布了季度财报。该公司报告季度每股收益为（0.85 美元），低于分析师共识预期的（0.77 美元）0.08 美元。该公司季度收入为 97 万美元，而分析师预期为 333 万美元。Eyepoint Pharmaceuticals 的股本回报率为-63.80%，净利润率为-337.93%。整体来看，股票分析师预计 Eyepoint Pharmaceuticals, Inc.在本财年的每股收益将为-2.13 美元。</p>
<h2>机构投资者对 Eyepoint Pharmaceuticals 的看法</h2>
<p>对冲基金最近对该公司的持仓进行了调整。Nisa Investment Advisors LLC 在第二季度将其在 Eyepoint Pharmaceuticals 的持股增加了 1,636.5%。Nisa Investment Advisors LLC 目前拥有 2900 股该公司的股票，价值 27,000 美元，此前在上个季度购买了 2733 股。阿拉斯加州财政部在第三季度购买了 Eyepoint Pharmaceuticals 的新股份，价值约 50,000 美元。Russell Investments Group Ltd.在第三季度获得了 Eyepoint Pharmaceuticals 的新持仓，价值约 76,000 美元。Tower Research Capital LLC TRC 在第二季度将其在 Eyepoint Pharmaceuticals 的持股增加了 218.3%。Tower Research Capital LLC TRC 目前拥有 8700 股该公司的股票，价值 82,000 美元，此前在此期间又购买了 5967 股。最后，R Squared Ltd 在第二季度获得了 Eyepoint Pharmaceuticals 的新股份，价值约 100,000 美元。机构投资者和对冲基金持有该公司 99.41% 的股票。</p>
<h2>Eyepoint Pharmaceuticals 公司简介</h2>
<p>（获取免费报告）</p>
<p>EyePoint Pharmaceuticals, Inc.是一家临床阶段的生物制药公司，致力于开发和商业化治疗方案，以改善严重视网膜疾病患者的生活。该公司的产品线利用其专有的生物可降解 Durasert E 技术进行持续的眼内药物输送。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票，优于 Eyepoint Pharmaceuticals</li>
<li>电话会议和个人投资者</li>
<li>巴菲特减持苹果，退休前重注 Alphabet</li>
<li>低市盈率成长股：解锁投资机会</li>
<li>三家能源巨头提高股息——这对投资者意味着什么</li>
<li>两只上升的 CRM 平台股票，可能在 2025 年大幅上涨</li>
<li>为什么这三只科技股可能是你忽视的最佳机会</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Eyepoint Pharmaceuticals 吗？</h2>
<p>在考虑 Eyepoint Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Eyepoint Pharmaceuticals 并不在名单上。</p>
<p>虽然 Eyepoint Pharmaceuticals 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

EYPT

<p>Eyepoint Pharmaceuticals（纳斯达克代码：EYPT）股价上涨 8.6%，至 12.58 美元，交易量有所下降。分析师给予 “适度买入” 评级，目标价格范围为 23 美元至 39 美元。该公司报告的季度每股收益为（0.85 美元），未达到预期，收入为 97 万美元。机构投资者已调整其持仓，持有 99.41% 的股份。Eyepoint 专注于使用 Durasert E 技术治疗视网膜疾病</p>

<p>Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) shares shot up 8.6% on Monday . The company traded as high as $12.46 and last traded at $12.58. 292,616 shares were traded during mid-day trading, a decline of 68% from the average session volume of 911,497 shares. The stock had previously closed at $11.58.</p>
<div class="lb-trans"><p>Eyepoint Pharmaceuticals, Inc.（纳斯达克代码：EYPT - 获取免费报告）周一股价上涨了 8.6%。该公司股价最高达到 12.46 美元，最后交易价格为 12.58 美元。在午盘交易中，交易量为 292,616 股，较平均交易量 911,497 股下降了 68%。该股票之前的收盘价为 11.58 美元。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><ul>
<li>Breakout Momentum Plays You May Not Know About</li>
</ul>
<div class="lb-trans"><ul>
<li>你可能不知道的突破性动量股</li>
</ul>
</div><p>Several research firms recently weighed in on EYPT. HC Wainwright raised their price objective on Eyepoint Pharmaceuticals from $22.00 to $23.00 and gave the company a &#34;buy&#34; rating in a research note on Wednesday, August 6th. Chardan Capital restated a &#34;buy&#34; rating and issued a $27.00 price target on shares of Eyepoint Pharmaceuticals in a research report on Thursday, August 7th. Mizuho set a $28.00 price objective on shares of Eyepoint Pharmaceuticals in a research report on Monday, October 20th. Royal Bank Of Canada increased their price objective on shares of Eyepoint Pharmaceuticals from $28.00 to $39.00 and gave the company an &#34;outperform&#34; rating in a research note on Thursday, November 6th. Finally, Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Eyepoint Pharmaceuticals in a research report on Wednesday, October 8th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $30.00.</p>
<div class="lb-trans"><p>几家研究公司最近对 EYPT 进行了评估。HC Wainwright 将 Eyepoint Pharmaceuticals 的目标价格从 22.00 美元上调至 23.00 美元，并在 8 月 6 日的研究报告中给予该公司 “买入” 评级。Chardan Capital 在 8 月 7 日的研究报告中重申了 “买入” 评级，并对 Eyepoint Pharmaceuticals 的股票设定了 27.00 美元的目标价格。Mizuho 在 10 月 20 日的研究报告中对 Eyepoint Pharmaceuticals 的股票设定了 28.00 美元的目标价格。加拿大皇家银行在 11 月 6 日的研究报告中将 Eyepoint Pharmaceuticals 的目标价格从 28.00 美元上调至 39.00 美元，并给予该公司 “跑赢大盘” 评级。最后，Weiss Ratings 在 10 月 8 日的研究报告中重申了 Eyepoint Pharmaceuticals 的 “卖出（d-）” 评级。五位股票研究分析师对该股票给予了 “买入” 评级，一位分析师给予了 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，平均目标价格为 30.00 美元。</p>
</div><p><strong>Get Our Latest Stock Report on Eyepoint Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Eyepoint Pharmaceuticals 的最新股票报告</strong></p>
</div><h2>Eyepoint Pharmaceuticals Trading Up 12.3%</h2>
<div class="lb-trans"><h2>Eyepoint Pharmaceuticals 股价上涨 12.3%</h2>
</div><p>The stock has a market cap of $1.08 billion, a price-to-earnings ratio of -4.84 and a beta of 1.85. The firm's 50 day moving average is $12.76 and its two-hundred day moving average is $10.49.</p>
<div class="lb-trans"><p>该股票的市值为 10.8 亿美元，市盈率为-4.84，贝塔值为 1.85。该公司的 50 日移动平均线为 12.76 美元，200 日移动平均线为 10.49 美元。</p>
</div><p>Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.85) EPS for the quarter, missing analysts' consensus estimates of ($0.77) by ($0.08). The firm had revenue of $0.97 million for the quarter, compared to analysts' expectations of $3.33 million. Eyepoint Pharmaceuticals had a negative return on equity of 63.80% and a negative net margin of 337.93%. As a group, equities analysts expect that Eyepoint Pharmaceuticals, Inc. will post -2.13 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Eyepoint Pharmaceuticals（纳斯达克代码：EYPT - 获取免费报告）最近于 11 月 5 日发布了季度财报。该公司报告季度每股收益为（0.85 美元），低于分析师共识预期的（0.77 美元）0.08 美元。该公司季度收入为 97 万美元，而分析师预期为 333 万美元。Eyepoint Pharmaceuticals 的股本回报率为-63.80%，净利润率为-337.93%。整体来看，股票分析师预计 Eyepoint Pharmaceuticals, Inc.在本财年的每股收益将为-2.13 美元。</p>
</div><h2>Institutional Investors Weigh In On Eyepoint Pharmaceuticals</h2>
<div class="lb-trans"><h2>机构投资者对 Eyepoint Pharmaceuticals 的看法</h2>
</div><p>Hedge funds have recently made changes to their positions in the business. Nisa Investment Advisors LLC increased its stake in Eyepoint Pharmaceuticals by 1,636.5% in the second quarter. Nisa Investment Advisors LLC now owns 2,900 shares of the company's stock valued at $27,000 after purchasing an additional 2,733 shares during the last quarter. State of Alaska Department of Revenue purchased a new stake in Eyepoint Pharmaceuticals in the 3rd quarter valued at about $50,000. Russell Investments Group Ltd. acquired a new position in shares of Eyepoint Pharmaceuticals during the 3rd quarter valued at about $76,000. Tower Research Capital LLC TRC lifted its holdings in shares of Eyepoint Pharmaceuticals by 218.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 8,700 shares of the company's stock worth $82,000 after acquiring an additional 5,967 shares during the period. Finally, R Squared Ltd acquired a new stake in shares of Eyepoint Pharmaceuticals in the second quarter worth approximately $100,000. Institutional investors and hedge funds own 99.41% of the company's stock.</p>
<div class="lb-trans"><p>对冲基金最近对该公司的持仓进行了调整。Nisa Investment Advisors LLC 在第二季度将其在 Eyepoint Pharmaceuticals 的持股增加了 1,636.5%。Nisa Investment Advisors LLC 目前拥有 2900 股该公司的股票，价值 27,000 美元，此前在上个季度购买了 2733 股。阿拉斯加州财政部在第三季度购买了 Eyepoint Pharmaceuticals 的新股份，价值约 50,000 美元。Russell Investments Group Ltd.在第三季度获得了 Eyepoint Pharmaceuticals 的新持仓，价值约 76,000 美元。Tower Research Capital LLC TRC 在第二季度将其在 Eyepoint Pharmaceuticals 的持股增加了 218.3%。Tower Research Capital LLC TRC 目前拥有 8700 股该公司的股票，价值 82,000 美元，此前在此期间又购买了 5967 股。最后，R Squared Ltd 在第二季度获得了 Eyepoint Pharmaceuticals 的新股份，价值约 100,000 美元。机构投资者和对冲基金持有该公司 99.41% 的股票。</p>
</div><h2>Eyepoint Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Eyepoint Pharmaceuticals 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.</p>
<div class="lb-trans"><p>EyePoint Pharmaceuticals, Inc.是一家临床阶段的生物制药公司，致力于开发和商业化治疗方案，以改善严重视网膜疾病患者的生活。该公司的产品线利用其专有的生物可降解 Durasert E 技术进行持续的眼内药物输送。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Eyepoint Pharmaceuticals</li>
<li>Conference Calls and Individual Investors</li>
<li>Buffett Trims Apple, Bets Big on Alphabet Ahead of Retirement</li>
<li>Low PE Growth Stocks: Unlocking Investment Opportunities</li>
<li>3 Energy Giants Amp Up Dividends—Here’s What It Means for Investors</li>
<li>2 Rising CRM Platform Stocks That Can Surge Higher in 2025</li>
<li>Why These 3 Tech Stocks Could Be the Best Opportunities You're Overlooking</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，优于 Eyepoint Pharmaceuticals</li>
<li>电话会议和个人投资者</li>
<li>巴菲特减持苹果，退休前重注 Alphabet</li>
<li>低市盈率成长股：解锁投资机会</li>
<li>三家能源巨头提高股息——这对投资者意味着什么</li>
<li>两只上升的 CRM 平台股票，可能在 2025 年大幅上涨</li>
<li>为什么这三只科技股可能是你忽视的最佳机会</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Eyepoint Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Eyepoint Pharmaceuticals 吗？</h2>
</div><p>Before you consider Eyepoint Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Eyepoint Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eyepoint Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Eyepoint Pharmaceuticals 并不在名单上。</p>
</div><p>While Eyepoint Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Eyepoint Pharmaceuticals 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Eyepoint Pharmaceuticals（NASDAQ:EYPT）股价上涨 8.6% - 事件详情如下